In examining recent analyst actions, we gain insights into how financial experts perceive Humana. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings ...

Under this year’s star ratings, 94% of Humana’s MA enrollees ... Strategy firm Capstone believes the lawsuit is a smart move by Humana, an analyst note shared with Fierce Healthcare shows.

Humana (NYSE:HUM) loses an administrative appeal filed in response to its 2025 Medicare Star Ratings cut. Read more here.

The decision, which Humana disclosed in a Tuesday filing with the court overseeing its lawsuit against the HHS, will be ...

According to Humana, CMS miscalculated its scores, which spelled bad news for the company's finances because higher star ...

The firm has an Outperform rating on Humana. The Fly notes that back in October, Humana sued U.S. health agencies seeking to reverse a cut to crucial Medicare quality ratings, which translates to ...

Humana's stock has shown resilience, boosted by a 5% increase in Medicare Advantage payments. Read my analysis of HUM stock.

Morgan Stanley raised the firm’s price target on Humana (HUM) to $290 from $285 and keeps an Equal Weight rating on the shares. While policy ...

NYSE HUM opened at $280.63 on Monday. Humana has a 12 month low of $213.31 and a 12 month high of $406.46. The company’s 50-day moving average price is $266.00 and its 200-day moving average ...

The Centers for Medicare and Medicaid Services announced higher-than-expected Medicare Advantage payment rate increases for ...

Kepler Capital analyst Anton Lund maintained a Buy rating on Humana AB (47H – Research Report) on April 10 and set a price target of SEK50.00.